INVO to Launch Additional INVO Center in Tampa, Florida
INVO Bioscience, Inc. (NASDAQ: INVO) announced on February 16, 2022, plans to open a new INVO Center in Tampa, Florida. This center aims to provide advanced fertility care using the INVOcell® device, enhancing access for underserved patients. Currently, INVO operates centers in Birmingham, Atlanta, and Monterrey, with another center set to open in San Francisco. CEO Steve Shum emphasized the demographic suitability of Tampa for expanding fertility services. The company is also evaluating opportunities for further growth in other markets.
- Expansion of services with a new INVO Center in Tampa, enhancing local access to fertility care.
- INVO currently operates centers in Birmingham, Atlanta, and Monterrey, indicating successful business model implementation.
- Utilization of INVOcell® provides an effective, affordable alternative for patients seeking fertility treatment.
- None.
SARASOTA, Fla. and TAMPA, Fla., Feb. 16, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the IVC procedure it enables, today announced plans to open its next INVO Center in Tampa, Florida. The Tampa INVO Center will focus on patients in need of advanced fertility care utilizing the efficient, effective, and affordable INVOcell® solution. The company currently has three operational INVO Centers treating patients in Birmingham, Alabama, Atlanta, Georgia, and Monterrey, Mexico, with another scheduled to open in the San Francisco area.
"Following significant diligence and in consultation with industry experts, we are excited to announce Tampa as the next INVO Center location," commented Steve Shum, CEO of INVO. "The characteristics and demographics of the Tampa market lend themselves perfectly to our INVO Center approach focused on expanding access to advanced fertility services for the significantly underserved patient population. By leveraging the blueprint and experiences from our earlier centers, we look forward to opening the clinic in 2022 and advancing our mission of democratizing fertility care. We are also actively conducting due diligence in several other markets as we look to initiate further expansion of our INVO Center commercialization platform."
The company expects to engage physician partners, similar to the models deployed in its other centers.
About INVO Bioscience
We are a commercial-stage fertility company expanding access to advanced treatment worldwide. Our primary mission is to implement new medical technologies aimed at increasing the availability of affordable, high-quality, patient-centered fertility care. Our patented medical device, the INVOcell®, enables a revolutionary in vivo method of vaginal incubation. This treatment solution is the world's first intravaginal culture technique for the incubation of oocytes and sperm during fertilization and early embryo development. This technique, designated as "IVC," provides patients a more natural and intimate experience in comparison to other assisted reproductive technology (ART) treatments. The IVC procedure can deliver comparable results at a fraction of the cost of traditional in vitro fertilization (IVF) and is a significantly more effective treatment than intrauterine insemination (IUI). Our commercialization strategy involves the opening of dedicated INVO Centers focused on offering the INVOcell® and IVC procedure (with 3 centers in North America now operational), as well as selling our technology solution into existing fertility clinics. For more information, please visit www.invobio.com.
Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
View original content to download multimedia:https://www.prnewswire.com/news-releases/invo-to-launch-additional-invo-center-in-tampa-florida-301483263.html
SOURCE INVO Bioscience, Inc.
FAQ
What is the purpose of the new INVO Center in Tampa, Florida?
When is the Tampa INVO Center expected to open?
Where are the other INVO Centers located?
What is the INVOcell® solution?
Who is leading INVO Bioscience?
